With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.122833-04-9,2-Methoxy-4-(4-methylpiperazin-1-yl)aniline,as a common compound, the synthetic route is as follows.
A mixture of IV-II-l-c (28 mg, 0.1 mmol), 2-methoxy-4-(4-methylpiperazin-l- yl)benzenamine (22 mg, 0.1 mmol), X-Phos (4.3 mg), Pd2(dba)3 (5.5 mg) and K2CO3 (41.5 mg, 0.3 mmol) in 1.2 mL of t-BuOH was heated at 100 0C in a seal tube for 4 h. Then the reaction was filtered through celite and eluted with dichloromethane. The dichloromethane was removed in vacuo and the resulting crude product was purified by preparative TLC with 3.5 N ammonia methanol solution and dichloromethane (1/25, v/v) to give the title compound IV-I (8 mg). 1H NMR (600 MHz, CDCl3) delta 8.32 (s, IH), 8.18 (d, J= 8.4 Hz, IH), 7.80 (dd, J= 1.8, 7.8 Hz, IH), 7.61 (s, IH), 7.51 (dd, J= 1.8, 7.8 Hz, IH), 7.40-7.34 (m, 2H), 6.54 (dd, J= 1.8, 8.4 Hz, IH), 6.52 (d, J= 1.8 Hz, IH), 3.85 (s, 3H), 3.55 (s, 3H), 3.23 (s, br, 4H), 2.69 (s, br, 4H), 2.43 (s, 3H). MS (ESI) m/z 463 (M+H)+.
122833-04-9, As the paragraph descriping shows that 122833-04-9 is playing an increasingly important role.
Reference£º
Patent; DANA FARBER CANCER INSTITUTE; GRAY, Nathanael, S.; DENG, Xianming; KWIATKOWSKI, Nicholas, Paul; WO2010/80712; (2010); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics